No Clear Winner in BMS, Exelixis/Ipsen First-line Renal Cancer Race
Executive Summary
While the CheckMate-214 data on the Opdivo/Yervoy combo made the headlines at ESMO, a closer look at the results show there is plenty of room for Cabometyx to have sizeable market share.
You may also be interested in...
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.
Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.
Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter
The use of the emerging tumor mutation burden biomarker and its relevance to the outcome of the CheckMate 227 study of Opdivo/Yervoy in first-line lung cancer was a hot topic during Bristol's Q3 earnings call, but questions remain.